Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ertumaxomab in HER2+ Metastatic Breast Cancer
NCT00522457Phase 2Terminated
- Sponsor
- Neovii Pharmaceuticals
- Start
- Jan 2008
- Primary completion
- Dec 2009
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of ertumaxomab in breast cancer, sponsored by Neovii Pharmaceuticals. Primary endpoint: Objective Response Rate at 6 months. Started Jan 2008; status: terminated.
02
Drugs
ertumaxomab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00522457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00522457.